Akorn expects U.S. FDA inspection of India site by late 2015, early 2016 As a first step, we have implemented Akorn's global quality policies at the Akorn India site. We are now in the process of implementing our plan to transfer existing or file new products to trigger U.S. FDA facility inspections by late 2013 or early 2014. The proposed oncology facility and expanded injectable facility should be completed by late 2014, and we expect the U.S. FDA to inspect these facilities by late 2015 or early 2016.
Akorn initiated with Outperform, $50 target at William Blair William Blair started shares of Akorn with an Outperform rating and $50 price target. The firm says the maker of ophthalmic and hospital-based injectable therapies is one of the fastest-growing companies in the specialty pharmaceuticals sector. William Blair thinks consolidation will likely continue within the specialty/generics market and feels Akorn represents an attractive asset. The stock closed yesterday up 38c to $39.75.